BMS 502

BMS 502 is an inhibitor of diacylglycerol kinase alpha (DGK-alpha), DGK-zeta, and DGK-iota (IC50s = 0.0046, 0.0021, and 0.0026 µM, respectively). It is selective for these DGKs over DGK-beta, DGK-gamma, and DGK-kappa (IC50s = 1, 0.68, and 4.6 µM, respectively). BMS 502 increases levels of IFN-gamma and phosphorylation of ERK in isolated human whole blood (EC50s = 0.28 and 0.52 µM, respectively). It also increases the proliferation of CD8+ T cells (EC50 = 0.065 µM), which express DGK-alpha and DGK-zeta but not DGK-iota. BMS 502 (0.3-10 mg/kg) increases the frequency of CD69+CD8+ T cells when administered in combination with the peptide antigen SIINFEKL in OT I mice, which express modified murine T cell receptors that recognize SIINFEKL.Formal Name: 8-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]-5,6-dihydro-5-methyl-7-nitro-6-oxo-1,5-naphthyridine-2-carbonitrile. CAS Number: 2407854-18-4. Molecular Formula: C27H22F2N6O3. Formula Weight: 516.5. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMF: 10 mg/ml, DMSO: 1 mg/ml. lambdamax: 232 nm. SMILES: N#CC1=NC(C(N2CCN(C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2)=C5[N+]([O-])=O)=C(C=C1)N(C)C5=O. InChi Code: InChI=1S/C27H22F2N6O3/c1-32-22-11-10-21(16-30)31-23(22)25(26(27(32)36)35(37)38)34-14-12-33(13-15-34)24(17-2-6-19(28)7-3-17)18-4-8-20(29)9-5-18/h2-11,24H,12-15H2,1H3. InChi Key: XAHMIJCNFUSTMT-UHFFFAOYSA-N.